Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07422285 · ClinicalTrials.gov registry record · Phase 1
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
A Phase 1 study of Healthy Participants and Pharmacokinetics, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 400
- Enrollment target
- 4
- Study locations
NCT07422285 is a Phase 1 study of Healthy Participants and Pharmacokinetics that is actively recruiting participants, run by Amgen. The registered enrollment target is 400 participants, above the 62-participant average among 119 other Healthy Participants trials with a reported enrollment target (545% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT07422285, a Phase 1 study of Healthy Participants and Pharmacokinetics, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 400 participants
- Enrollment target
- 4
- Study locations
Study Summary
The main objective of this trial is to evaluate the pharmacokinetics of two evolocumab drug products in healthy participants.
Conditions Studied
Interventions
- DRUG Evolocumab Drug Substance A
- DRUG Evolocumab Drug Substance B
Study Locations (4)
Florida
- Fortrea Clinical Research Unit - Daytona Beach - Daytona Beach
Missouri
- QPS Bio-Kinetic - Springfield
Texas
- Fortrea Clinical Research Unit - Dallas - Dallas
Wisconsin
- Fortrea Clinical Research Unit Inc. - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-01-16 |
| Est. Completion | 2026-07-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07422285
The ClinicalTrials.gov registry entry for NCT07422285 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 62-participant average among 119 other Healthy Participants trials with a reported enrollment target (545% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Evolocumab Drug Substance A is the first listed.
NCT07422285 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT07422285 about?
NCT07422285 is a clinical study titled "Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose". The main objective of this trial is to evaluate the pharmacokinetics of two evolocumab drug products in healthy participants.
What is the current status of trial NCT07422285?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 400 participants. The study started on 2026-01-16. Estimated completion is 2026-07-07.
What conditions does trial NCT07422285 study?
This clinical trial studies the following conditions: Healthy Participants, Pharmacokinetics.
What interventions are being tested in trial NCT07422285?
The interventions under investigation include: Evolocumab Drug Substance A (DRUG), Evolocumab Drug Substance B (DRUG).
Who is sponsoring clinical trial NCT07422285?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07422285 being conducted?
This trial has 4 study locations across Florida, Missouri, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.